Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein

Human Gene Therapy Methods

Volumn 25, Issue 3, 2014, Pages 187-196

  Vannoy, Charles H ^a   Xu, Lei ^a   Keramaris, Elizabeth ^a   Lu, Pei ^a   Xiao, Xiao ^b   Lu, Qi Long ^a  

^a LEVINE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; FUKUTIN RELATED PROTEIN; GLYCOSYLTRANSFERASE; GLYCOSYLTRANSFERASE LARGE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; DYSTROGLYCAN; FKRP PROTEIN, HUMAN; LARGE PROTEIN, HUMAN; N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSTROGLYCANOPATHY; GENE OVEREXPRESSION; LOSS OF FUNCTION MUTATION; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TREATMENT OUTCOME; VIRAL GENE THERAPY; ANIMAL; CELL LINE; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; GLYCOSYLATION; HEART MUSCLE; HUMAN; METABOLISM; MUSCULAR DYSTROPHIES; MUTATION; PATHOLOGY; PHENOTYPE; SKELETAL MUSCLE;

ANIMALS; CELL LINE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DYSTROGLYCANS; GENETIC THERAPY; GENETIC VECTORS; GLYCOSYLATION; HUMANS; MICE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUTATION; MYOCARDIUM; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHENOTYPE; PROTEINS;

EID: 84902588556     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2013.151     Document Type: Article

References (42)

1. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype-And tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510
2. Barresi, R., Michele, D.E., Kanagawa, M., et al. (2004). LARGE can functionally bypass a-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 10, 696-703
3. Beltrán-Valero De Bernabé, D., Currier, S., Steinbrecher, A., et al. (2002). Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am. J. Hum. Genet. 71, 1033-1043
4. Beltra'n-Valero De Bernabé, D., Voit, T., Longman, C., et al. (2004).Mutations in the FKRP gene can causemuscle-eye-brain disease andWalker-Warburg syndrome. J.Med.Genet. 41, e61
5. Blaeser, A., Keramaris, E., Chan, Y., et al. (2013). Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Hum. Genet. 132, 923-934
6. Brockington, M., Torelli, S., Prandini, P., et al. (2005). Localization and functional analysis of the LARGE family of glycosyltransferases: Significance for muscular dystrophy. Hum. Mol. Genet. 14, 657-665
7. Brockington, M., Torelli, S., Sharp, P.S., et al. (2010). Transgenic overexpression of LARGE induces a-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS ONE 5, e14434
8. Brown, S.C., Torelli, S., Brockington, M., et al. (2004). Abnormalities in a-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am. J. Pathol. 164, 727-737
9. Campanelli, J.T., Roberds, S.L., Campbell, K.P., and Scheller, R.H. (1994). A role for dystrophin-Associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell 77, 663-674
10. Campbell, K.P. (1995). Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-679
11. Chan, Y.M., Keramaris-Vrantsis, E., Lidov, H.G., et al. (2010). Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum. Mol. Genet. 19, 3995-4006
12. Combs, A.C., and Ervasti, J.M. (2005). Enhanced laminin binding by a-dystroglycan after enzymatic deglycosylation. Biochem. J. 390, 303-309
13. Ervasti, J.M., and Campbell, K.P. (1991). Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121-1131
14. Ervasti, J., and Campbell, K. (1993). A role for the dystrophinglycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809-823
15. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., et al. (1990). Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319
16. EVan, G.I., Lewis, G.K., Ramsay, G., and Bishop, J.M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5, 3610-3616
17. Gee, S.H., Montanaro, F., Lindenbaum, M.H., and Carbonetto, S. (1994). Dystroglycan-A, a dystrophin-Associated glycoprotein, is a functional agrin receptor. Cell 77, 675-686
18. Grewal, P.K., Mclaughlan, J.M., Moore, C.J., et al. (2005). Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology 15, 912-923
19. Hu, Y., Li, Z-F., Wu, X., and Lu, Q. (2011). Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on alpha-dystroglycan. PLoS ONE 6, e16866
20. Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., et al. (1992). Primary structure of dystrophin-Associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696-702
21. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53
22. Inamori, K-I., Yoshida-Moriguchi, T., Hara, Y., et al. (2012). Dystroglycan function requires xylosyl-And glucuronyltransferase activities of LARGE. Science 335, 93-96
23. Kuga, A., Kanagawa, M., Sudo, A., et al. (2012). Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-Type tissues expressing non-laminin binding form of a-dystroglycan. J. Biol. Chem. 287, 9560-9567
24. Manya, H., Chiba, A., Yoshida, A., et al. (2004). Demonstration of mammalian protein O-mannosyltransferase activity: Coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. USA 101, 500-505
25. Mercuri, E., Topaloglu, H., Brockington, M., et al. (2006). Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch. Neurol. 63, 251-257
26. Ogawa, M., Nakamura, N., Nakayama, Y., et al. (2013). GTDC2 modifies O-mannosylated a-dystroglycan in the endoplasmic reticulum to generate N-Acetyl glucosamine epitopes reactive with CTD110.6 antibody. Biochem. Biophys. Res. Commun. 440, 88-93
27. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., et al. (2006). Recombinant adeno-Associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-e9
28. Patnaik, S.K., and Stanley, P. (2005). Mouse Large can modify complex N-And mucin O-glycans on a-dystroglycan to induce laminin binding. J. Biol. Chem. 280, 20851-20859
29. Rohr, U-P., Heyd, F., Neukirchen, J., et al. (2005). Quantitative real-Time PCR for titration of infectious recombinant AAV-2 particles. J. Virol. Methods 127, 40-45
30. Roscioli, T., Kamsteeg, E-J., Buysse, K., et al. (2012). Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of a-dystroglycan. Nat. Genet. 44, 581-585
31. Stevens, E., Carss Keren, j., Cirak, S., et al. (2013). Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of a-dystroglycan. Am. J. Hum. Genet. 92, 354-365
32. Talts, J.F., Andac, Z., Gohring, W., et al. (1999). Binding of the G domains of laminin a1 and a2 chains and perlecan to heparin, sulfatides, a-dystroglycan and several extracellular matrix proteins. EMBO J. 18, 863-870
33. Toda, T., Kobayashi, K., Kondo-Iida, E., et al. (2000). The Fukuyama congenital muscular dystrophy story. Neuromuscul. Disord. 10, 153-159
34. Van Reeuwijk, J., Janssen, M., Van Den Elzen, C., et al. (2005). POMT2 mutations cause a-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42, 907-912
35. Veldwijk, M.R., Topaly, J., Laufs, S., et al. (2002). Development and optimization of a real-Time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272-278
36. Whitmore, C., Fernandez-Fuente, M., Booler, H., et al. (2013). The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum. Mol. Genet. 23, 1842-1855
37. Xiao, X., Li, J., and Samulski, R.J. (1998). Production of high-Titer recombinant adeno-Associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232
38. Xu, L., Lu, P.J., Wang, C-H., et al. (2013). Adeno-Associated virus 9 mediated FKRP gene therapy restores functional glycosylation of a-dystroglycan and improves muscle functions. Mol. Ther. 10, 1832-1840
39. Yoshida, M., and Ozawa, E. (1990). Glycoprotein complex anchoring dystrophin to sarcolemma. J. Biochem. (Tokyo) 108, 748-752
40. Yoshida, A., Kobayashi, K., Manya, H., et al. (2001). Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1, 717-724. (Pubitemid 33586123)
41. Yu, M., He, Y., Wang, K., et al. (2013). Adeno-Associated viralmediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum. Gene Ther. 24, 317-330
42. Zhang, P., and Hu, H. (2012). Differential glycosylation of a-dystroglycan and proteins other than a-dystroglycan by like- glycosyltransferase. Glycobiology 22, 235-247.